- Home
- CENX vs MNKD Comparison
CENX vs MNKD Comparison
Compare CENX & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CENX
- MNKD
- Stock Information
- Founded
- CENX 1995
- MNKD 1991
- Country
- CENX United States
- MNKD United States
- Employees
- CENX N/A
- MNKD N/A
- Industry
- CENX Aluminum
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- CENX Industrials
- MNKD Health Care
- Exchange
- CENX Nasdaq
- MNKD Nasdaq
- Market Cap
- CENX 1.9B
- MNKD 1.6B
- IPO Year
- CENX 1996
- MNKD 2004
- Fundamental
- Price
- CENX $15.59
- MNKD $4.54
- Analyst Decision
- CENX Strong Buy
- MNKD Buy
- Analyst Count
- CENX 3
- MNKD 6
- Target Price
- CENX $23.00
- MNKD $8.92
- AVG Volume (30 Days)
- CENX 1.9M
- MNKD 2.2M
- Earning Date
- CENX 04-30-2025
- MNKD 05-07-2025
- Dividend Yield
- CENX N/A
- MNKD N/A
- EPS Growth
- CENX N/A
- MNKD N/A
- EPS
- CENX 3.27
- MNKD 0.10
- Revenue
- CENX $2,220,300,000.00
- MNKD $285,504,000.00
- Revenue This Year
- CENX $8.59
- MNKD $14.23
- Revenue Next Year
- CENX $6.39
- MNKD $14.56
- P/E Ratio
- CENX $4.77
- MNKD $45.40
- Revenue Growth
- CENX 1.60
- MNKD 43.50
- 52 Week Low
- CENX $11.40
- MNKD $3.97
- 52 Week High
- CENX $25.39
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- CENX 41.81
- MNKD 28.12
- Support Level
- CENX $13.05
- MNKD $4.34
- Resistance Level
- CENX $16.10
- MNKD $4.72
- Average True Range (ATR)
- CENX 1.40
- MNKD 0.21
- MACD
- CENX -0.06
- MNKD -0.01
- Stochastic Oscillator
- CENX 44.64
- MNKD 27.03
About CENX Century Aluminum Company
Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. Century purchases nearly all of its alumina from Glencore. The company produces high purity aluminum, standard grade aluminum sow and tee bars, and value-added billet and foundry products. Century also owns a carbon anode production facility in the Netherlands.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.